首页 > 最新文献

American journal of translational research最新文献

英文 中文
The antimicrobial effect of Curcuma longa and Allium sativum decoction in rats explains its utility in wound care. 莪术和薤白煎剂对大鼠的抗菌作用说明了它在伤口护理方面的实用性。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-25 eCollection Date: 2024-01-01 DOI: 10.62347/WUTE6317
Maliha Khalid Khan, Imran Ahmad Khan, Muhammad Omer Iqbal, Emad M Eed, Aftab Ahmad, Muhammad Naeem, Hafiza Tuba Ashiq, Nayla Munawar

Objective: In South Asia, Curcuma longa and Allium sativum are extensively used as household remedies for wound care for veterinary and human infectious diseases. However, little pharmacologic data is present to support this folklore. A series of in vitro and in vivo experiments were conducted to validate the folkloric practice of these herbs.

Methods: In vitro experiments, phytochemistry, polyphenolic content, acute dose dermal toxicity, antimicrobial activity, and antioxidant assays were conducted. For in vivo experiments, the decoction was prepared and tested for a wound cure against an experimentally induced excision wound on the dorsal region of rats under ketamine anesthesia. Rats were divided into five groups (5 rats in each). Group 1 was treated with standard Povidone-Iodine, Group 2 was treated with distilled water, group 3 received topical application of the decoction, Group 4 received topical as well as 1 mL oral decoction, and Group 5 received topical as well as oral 1 mL water. Histopathology, leukocyte count and acute oral dose toxicity were estimated.

Result: After the ninth post-wounding day, the wound contractions recorded in each group were group-1 (83.11%), group-2 (19.21%), group-3 (91.01%), group-4 (100%), and group-5 (16.55%) similarly less cytoarchitectural damage and more promising cellular repair were observed in both decoctions treated groups as compared to standard and control. A less exaggerated WBC profile was recorded in decoction-treated groups compared to standard and control, while decoction showed significant antibacterial potential even against the resistance strains of standard antibiotics. Decoction showed no dermal and oral toxicity in the animals tested.

Conclusion: Decoction of A. sativum and C. longa possesses excellent wound healing potential because of the variety of phytoconstituents linked to the antibacterial, antioxidant, and immunomodulator spectrum and can be used as an effective household remedy for wound healing with no notable toxicity.

目的:在南亚,莪术和薤白被广泛用作治疗兽医和人类传染病伤口的家庭药方。然而,支持这一民间传说的药理数据却很少。为了验证这些草药的民间做法,我们进行了一系列体外和体内实验:方法:进行了体外实验、植物化学、多酚含量、急性剂量皮肤毒性、抗菌活性和抗氧化测定。在活体实验中,大鼠在氯胺酮麻醉下,用煎煮法对实验诱导的大鼠背侧切除伤口进行伤口治愈测试。大鼠被分为五组(每组五只)。第 1 组用标准聚维酮碘治疗,第 2 组用蒸馏水治疗,第 3 组局部涂抹煎剂,第 4 组局部涂抹并口服 1 毫升煎剂,第 5 组局部涂抹并口服 1 毫升水。对组织病理学、白细胞计数和急性口服剂量毒性进行了估计:伤口愈合后第九天,各组的伤口收缩率分别为:第 1 组(83.11%)、第 2 组(19.21%)、第 3 组(91.01%)、第 4 组(100%)和第 5 组(16.55%)。与标准组和对照组相比,煎剂处理组的白细胞数量减少,煎剂甚至对标准抗生素的耐药菌株也有显著的抗菌潜力。煎剂对接受测试的动物没有皮肤和口服毒性:结论:莴苣和龙舌兰的煎剂具有很好的伤口愈合潜力,因为其中含有多种与抗菌、抗氧化和免疫调节有关的植物成分,可作为一种有效的家庭疗法用于伤口愈合,且无明显毒性。
{"title":"The antimicrobial effect of <i>Curcuma longa</i> and <i>Allium sativum decoction</i> in rats explains its utility in wound care.","authors":"Maliha Khalid Khan, Imran Ahmad Khan, Muhammad Omer Iqbal, Emad M Eed, Aftab Ahmad, Muhammad Naeem, Hafiza Tuba Ashiq, Nayla Munawar","doi":"10.62347/WUTE6317","DOIUrl":"10.62347/WUTE6317","url":null,"abstract":"<p><strong>Objective: </strong><i>In South Asia</i>, <i>Curcuma longa</i> and <i>Allium sativum</i> are extensively used as household remedies for wound care for veterinary and human infectious diseases. However, little pharmacologic data is present to support this folklore. A series of <i>in vitro</i> and <i>in vivo</i> experiments were conducted to validate the folkloric practice of these herbs.</p><p><strong>Methods: </strong><i>In vitro</i> experiments, phytochemistry, polyphenolic content, acute dose dermal toxicity, antimicrobial activity, and antioxidant assays were conducted. For <i>in vivo</i> experiments, the decoction was prepared and tested for a wound cure against an experimentally induced excision wound on the dorsal region of rats under ketamine anesthesia. Rats were divided into five groups (5 rats in each). Group 1 was treated with standard Povidone-Iodine, Group 2 was treated with distilled water, group 3 received topical application of the decoction, Group 4 received topical as well as 1 mL oral decoction, and Group 5 received topical as well as oral 1 mL water. Histopathology, leukocyte count and acute oral dose toxicity were estimated.</p><p><strong>Result: </strong>After the ninth post-wounding day, the wound contractions recorded in each group were group-1 (83.11%), group-2 (19.21%), group-3 (91.01%), group-4 (100%), and group-5 (16.55%) similarly less cytoarchitectural damage and more promising cellular repair were observed in both decoctions treated groups as compared to standard and control. A less exaggerated WBC profile was recorded in decoction-treated groups compared to standard and control, while decoction showed significant antibacterial potential even against the resistance strains of standard antibiotics. Decoction showed no dermal and oral toxicity in the animals tested.</p><p><strong>Conclusion: </strong>Decoction of <i>A. sativum</i> and <i>C. longa</i> possesses excellent wound healing potential because of the variety of phytoconstituents linked to the antibacterial, antioxidant, and immunomodulator spectrum and can be used as an effective household remedy for wound healing with no notable toxicity.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"6159-6167"},"PeriodicalIF":1.7,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protection against cigarette smoke-induced chronic obstructive pulmonary disease via activation of the SIRT1/FoxO1 axis by targeting microRNA-132. 通过靶向 microRNA-132 激活 SIRT1/FoxO1 轴,防止香烟烟雾诱发慢性阻塞性肺病。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.62347/FVQP4019
Qin Shen, Jing Chen, Suzhen Yang, Hui Zhang, Hui Yu, Sha Wang, Jianmin Li

Objective: To investigate the biological role of miR-132 in a murine model of chronic obstructive pulmonary disease (COPD) via activation of the SIRT1/FoxO1 axis.

Methods: COPD was induced in C57BL/6J male mice by exposing them to cigarette smoke (CS) for 8 weeks. A miR-132 knockout mouse model was used to assess the role of miR-132 in CS-induced COPD. Lung tissue apoptosis was evaluated using TUNEL assays and histopathology, along with lung functional tests which were performed to assess CS-induced lung injury.

Results: Elevated miR-132 expression was observed in lung tissues and bronchoalveolar lavage fluid in COPD mice. miR-132 depletion improved lung function, restored lung tissue morphology, and reduced apoptosis. Target prediction software identified miR-132 as a potential repressor of SIRT1. In COPD mice, SIRT1 and FoxO1 expression were reduced, but miR-132 knockout restored their levels.

Conclusion: Inhibition of miR-132 may serve as a therapeutic strategy for CS-induced COPD.

目的通过激活 SIRT1/FoxO1 轴,研究 miR-132 在慢性阻塞性肺病(COPD)小鼠模型中的生物学作用:方法:将C57BL/6J雄性小鼠暴露于香烟烟雾(CS)中8周,诱导其患慢性阻塞性肺病。采用 miR-132 基因敲除小鼠模型来评估 miR-132 在 CS 诱导的慢性阻塞性肺病中的作用。使用 TUNEL 检测法和组织病理学评估肺组织凋亡,同时进行肺功能测试,以评估 CS 诱导的肺损伤:结果:在慢性阻塞性肺病小鼠的肺组织和支气管肺泡灌洗液中观察到 miR-132 表达升高。目标预测软件确定 miR-132 是 SIRT1 的潜在抑制因子。在慢性阻塞性肺病小鼠中,SIRT1和FoxO1的表达减少,但敲除miR-132可恢复它们的表达水平:结论:抑制 miR-132 可作为 CS 诱导的慢性阻塞性肺病的一种治疗策略。
{"title":"Protection against cigarette smoke-induced chronic obstructive pulmonary disease via activation of the SIRT1/FoxO1 axis by targeting microRNA-132.","authors":"Qin Shen, Jing Chen, Suzhen Yang, Hui Zhang, Hui Yu, Sha Wang, Jianmin Li","doi":"10.62347/FVQP4019","DOIUrl":"10.62347/FVQP4019","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the biological role of miR-132 in a murine model of chronic obstructive pulmonary disease (COPD) via activation of the SIRT1/FoxO1 axis.</p><p><strong>Methods: </strong>COPD was induced in C57BL/6J male mice by exposing them to cigarette smoke (CS) for 8 weeks. A miR-132 knockout mouse model was used to assess the role of miR-132 in CS-induced COPD. Lung tissue apoptosis was evaluated using TUNEL assays and histopathology, along with lung functional tests which were performed to assess CS-induced lung injury.</p><p><strong>Results: </strong>Elevated miR-132 expression was observed in lung tissues and bronchoalveolar lavage fluid in COPD mice. miR-132 depletion improved lung function, restored lung tissue morphology, and reduced apoptosis. Target prediction software identified miR-132 as a potential repressor of SIRT1. In COPD mice, SIRT1 and FoxO1 expression were reduced, but miR-132 knockout restored their levels.</p><p><strong>Conclusion: </strong>Inhibition of miR-132 may serve as a therapeutic strategy for CS-induced COPD.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"5516-5524"},"PeriodicalIF":1.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of T-cell large granular lymphocytic leukemia with autoimmune hemolytic anemia and literature review. 一例 T 细胞大颗粒淋巴细胞白血病合并自身免疫性溶血性贫血及文献综述。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.62347/URFI7647
Shu-Yu Wang, Yan Li

T-cell large granular lymphocyte leukemia (T-LGLL), which is associated with autoimmune diseases, has been described. However, T-LGLL with B-cell dyscrasias presenting as autoimmune hemolytic anemia has been less frequently reported. Here, we report a rare case of combined papillary thyroid cancer (PTC), discuss the possible relationship between autoimmune hemolytic anemia (AIHA) and TLGLL, and review the literature. The patient presented with pancytopenia and systemic jaundice. Fortunately, the patient responded well to hormone and immunosuppressive (methotrexate) therapy. However, this insight is based on one rare case, and the pathogenesis of this disease requires further clinical research for clarification.

与自身免疫性疾病相关的 T 细胞大颗粒淋巴细胞白血病(T-LGLL)已有报道。然而,T-LGLL伴有B细胞异常,表现为自身免疫性溶血性贫血的病例却鲜有报道。在此,我们报告了一例罕见的合并甲状腺乳头状癌(PTC)的病例,讨论了自身免疫性溶血性贫血(AIHA)与 TLGLL 之间可能存在的关系,并回顾了相关文献。患者出现全血细胞减少和全身性黄疸。幸运的是,患者对激素和免疫抑制剂(甲氨蝶呤)治疗反应良好。然而,这一见解只是基于一个罕见病例,该病的发病机制还需要进一步的临床研究才能明确。
{"title":"A case of T-cell large granular lymphocytic leukemia with autoimmune hemolytic anemia and literature review.","authors":"Shu-Yu Wang, Yan Li","doi":"10.62347/URFI7647","DOIUrl":"10.62347/URFI7647","url":null,"abstract":"<p><p>T-cell large granular lymphocyte leukemia (T-LGLL), which is associated with autoimmune diseases, has been described. However, T-LGLL with B-cell dyscrasias presenting as autoimmune hemolytic anemia has been less frequently reported. Here, we report a rare case of combined papillary thyroid cancer (PTC), discuss the possible relationship between autoimmune hemolytic anemia (AIHA) and TLGLL, and review the literature. The patient presented with pancytopenia and systemic jaundice. Fortunately, the patient responded well to hormone and immunosuppressive (methotrexate) therapy. However, this insight is based on one rare case, and the pathogenesis of this disease requires further clinical research for clarification.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"5735-5742"},"PeriodicalIF":1.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of FOLFOX regimen combined with cetuximab treatment on the efficacy and tumor markers of advanced colon cancer patients. FOLFOX 方案联合西妥昔单抗治疗对晚期结肠癌患者疗效和肿瘤标志物的影响
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.62347/KENB9486
Yang Zhang, Hong Qian, Xiaofei Cheng, Ting Zhou, Cheng Zhong, Feng Tian, Qi Sun

Objective: To evaluate the efficacy of FOLFOX regimen combined with cetuximab in the treatment of advanced colon cancer.

Methods: This retrospective study involved 60 patients with primary colon cancer who were treated in the PLA Navy Anqing Hospital from January 2022 to February 2023. According to their treatment regimen, the patients were divided into a treatment group that received FOLFOX4 combined with cetuximab (n=30), and a control group treated with cetuximab alone (n=30). The general data of the two groups were compared, and the short-term response rate was assessed by comparing the proportions of complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD) between the two groups. In addition, the progression free survival (PFS) and overall survival (OS) were compared between the two groups, along with the adverse reactions and changes in serum tumor marker (CEA and CA19-9) levels.

Result: The observation group showed a significantly higher short-term effective rate (CR+PR) compared to the control group (56.67% vs. 23.33%). The PFS and OS of the observation group were markedly longer compared to the control group. In terms of adverse reactions, the incidence of neutropenia, thrombocytopenia, nausea, vomiting, and diarrhea was similar between the two groups; however, the incidence of rash in the observation group was higher. After the treatment, the serum CEA and CA19-9 levels decreased markedly in both groups, and the observation group demonstrated obviously lower levels than the control group (P<0.001). Similarly, the decreases in VEGF-A and VEGFR2 levels in the observation group were more significant than those in the control group (all P<0.001).

Conclusion: Despite inducing rash, which is controllable, the combined therapy of FOLFOX and cetuximab significantly improves short-term efficacy, reduces the levels of CEA, CA19-9, VEGF-A and VEGFR2, and extends the PFS and OS of patients, which can be served as an effective treatment strategy for advanced colon cancer.

目的:评估 FOLFOX 方案联合西妥昔单抗治疗晚期结肠癌的疗效:评估FOLFOX方案联合西妥昔单抗治疗晚期结肠癌的疗效:本回顾性研究涉及中国人民解放军海军安庆医院自2022年1月至2023年2月收治的60例原发性结肠癌患者。根据患者的治疗方案,将其分为FOLFOX4联合西妥昔单抗治疗组(30例)和单用西妥昔单抗治疗的对照组(30例)。比较两组的一般数据,并通过比较两组完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和疾病进展(PD)的比例来评估短期反应率。此外,还比较了两组的无进展生存期(PFS)和总生存期(OS),以及不良反应和血清肿瘤标志物(CEA和CA19-9)水平的变化:结果:观察组的短期有效率(CR+PR)明显高于对照组(56.67% vs. 23.33%)。观察组的PFS和OS明显长于对照组。在不良反应方面,两组中性粒细胞减少、血小板减少、恶心、呕吐和腹泻的发生率相似,但观察组皮疹的发生率较高。治疗后,两组患者的血清 CEA 和 CA19-9 水平均明显下降,观察组明显低于对照组(PC 结论:尽管会诱发皮疹,但皮疹是一种罕见的致癌物质:FOLFOX与西妥昔单抗联合治疗虽然会诱发皮疹,但皮疹是可控的,而且能显著提高短期疗效,降低CEA、CA19-9、VEGF-A和VEGFR2水平,延长患者的PFS和OS,可作为晚期结肠癌的有效治疗策略。
{"title":"Effect of FOLFOX regimen combined with cetuximab treatment on the efficacy and tumor markers of advanced colon cancer patients.","authors":"Yang Zhang, Hong Qian, Xiaofei Cheng, Ting Zhou, Cheng Zhong, Feng Tian, Qi Sun","doi":"10.62347/KENB9486","DOIUrl":"10.62347/KENB9486","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy of FOLFOX regimen combined with cetuximab in the treatment of advanced colon cancer.</p><p><strong>Methods: </strong>This retrospective study involved 60 patients with primary colon cancer who were treated in the PLA Navy Anqing Hospital from January 2022 to February 2023. According to their treatment regimen, the patients were divided into a treatment group that received FOLFOX4 combined with cetuximab (n=30), and a control group treated with cetuximab alone (n=30). The general data of the two groups were compared, and the short-term response rate was assessed by comparing the proportions of complete remission (CR), partial remission (PR), stable disease (SD) and progressive disease (PD) between the two groups. In addition, the progression free survival (PFS) and overall survival (OS) were compared between the two groups, along with the adverse reactions and changes in serum tumor marker (CEA and CA19-9) levels.</p><p><strong>Result: </strong>The observation group showed a significantly higher short-term effective rate (CR+PR) compared to the control group (56.67% vs. 23.33%). The PFS and OS of the observation group were markedly longer compared to the control group. In terms of adverse reactions, the incidence of neutropenia, thrombocytopenia, nausea, vomiting, and diarrhea was similar between the two groups; however, the incidence of rash in the observation group was higher. After the treatment, the serum CEA and CA19-9 levels decreased markedly in both groups, and the observation group demonstrated obviously lower levels than the control group (P<0.001). Similarly, the decreases in VEGF-A and VEGFR2 levels in the observation group were more significant than those in the control group (all P<0.001).</p><p><strong>Conclusion: </strong>Despite inducing rash, which is controllable, the combined therapy of FOLFOX and cetuximab significantly improves short-term efficacy, reduces the levels of CEA, CA19-9, VEGF-A and VEGFR2, and extends the PFS and OS of patients, which can be served as an effective treatment strategy for advanced colon cancer.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"5676-5683"},"PeriodicalIF":1.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Indirubin induces apoptosis in ovarian cancer cells via the mitochondrial pathway. 靛红通过线粒体途径诱导卵巢癌细胞凋亡。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.62347/IOFY5604
Jinhua Wang, Lihong Chen, Qiaomei Zheng, Shaozhan Chen, Zhidan Hou, Peishu Liu

Objective: To investigate the pro-apoptotic effects of Indirubin, a traditional Chinese medicine, on ovarian cancer SKOV3 cell line and to explore its underlying mechanisms.

Methods: Ovarian cancer SKOV3 cells were divided into a control group (cells cultured normally) and an experimental group (cells cultured in medium containing Indirubin). SKOV3 cells at the logarithmic phase were treated with Indirubin at various concentrations. Cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8) assay and 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay, while apoptosis was detected by flow cytometry, TdT-mediated dUTP Nick-End Labeling (TUNEL) staining, and immunofluorescence. Transcriptome sequencing was conducted to screen for apoptosis-related factors. qPCR and western blot were used to detect the mRNA and protein expression on added of molecules related to mitochondrial permeability transition pores.

Results: MTT assay showed that Indirubin inhibited the growth of SKOV3 cells in both plate and sphere cultures, with IC50 values of 3.003 μM (plate culture) and 4.253 μM (sphere culture), respectively. Indirubin showed a lower inhibitory concentration than cisplatin (IC50 3.687 μM in plate culture and 7.023 μM in sphere culture), and its effect was comparable to adriamycin. Flow cytometry revealed an increase in apoptosis rates in SKOV3 cells treated with Indirubin. Transcriptome sequencing indicated significant changes in the transcription of various apoptosis-related genes, particularly those involved in the mitochondrial apoptosis pathway, such as Bcl-2-associated X protein (Bax) and Bcl2 associated agonist of cell death (Bad). After Indirubin treatment, the mRNA and protein expression levels of mitochondrial channel-related genes Cyclophilin D (CyPD), adenine nucleotide translocator 1 (ANT1), and voltage-dependent anion channel (VADC) were significantly elevated (all P < 0.05). By regulating the mitochondrial membrane permeability through the Bcl-2 family members, Indirubin promoted apoptosis in SKOV3 cells.

Conclusion: Indirubin inhibits the proliferation and promotes the apoptosis of ovarian cancer cells, exerting an anti-tumor effect. Its pro-apoptotic action is closely related to the mitochondrial apoptosis pathway.

目的:研究中药靛蓝对卵巢癌 SKOV3 细胞株的促凋亡作用及其机制:研究中药靛玉红对卵巢癌 SKOV3 细胞株的促凋亡作用,并探讨其潜在机制:方法:将卵巢癌 SKOV3 细胞分为对照组(正常培养)和实验组(在含靛玉红的培养基中培养)。用不同浓度的靛红处理对数期的 SKOV3 细胞。细胞增殖采用细胞计数试剂盒-8(CCK-8)检测法和 3-(4,5)-二甲基噻唑(-z-y1)-3,5-二苯基四唑鎓(MTT)检测法,细胞凋亡则采用流式细胞术、TdT 介导的 dUTP 镍端标记(TUNEL)染色法和免疫荧光法检测。采用 qPCR 和 western 印迹法检测线粒体通透性转换孔相关分子的 mRNA 和蛋白质表达:MTT试验表明,靛红抑制了SKOV3细胞在平板和球形培养物中的生长,IC50值分别为3.003 μM(平板培养物)和4.253 μM(球形培养物)。靛红的抑制浓度低于顺铂(板培养的 IC50 值为 3.687 μM,球培养的 IC50 值为 7.023 μM),其效果与阿霉素相当。流式细胞术显示,用靛红处理的 SKOV3 细胞的凋亡率有所增加。转录组测序表明,各种凋亡相关基因的转录发生了显著变化,尤其是那些参与线粒体凋亡途径的基因,如 Bcl-2 相关 X 蛋白(Bax)和 Bcl2 相关细胞死亡激动剂(Bad)。靛红处理后,线粒体通道相关基因嗜环蛋白D(CyPD)、腺嘌呤核苷酸转运体1(ANT1)和电压依赖性阴离子通道(VADC)的mRNA和蛋白表达水平显著升高(均P<0.05)。通过 Bcl-2 家族成员调节线粒体膜通透性,靛蓝促进了 SKOV3 细胞的凋亡:结论:靛玉红抑制卵巢癌细胞增殖,促进其凋亡,具有抗肿瘤作用。结论:靛玉红能抑制卵巢癌细胞增殖并促进其凋亡,具有抗肿瘤作用,其促进凋亡的作用与线粒体凋亡途径密切相关。
{"title":"Indirubin induces apoptosis in ovarian cancer cells via the mitochondrial pathway.","authors":"Jinhua Wang, Lihong Chen, Qiaomei Zheng, Shaozhan Chen, Zhidan Hou, Peishu Liu","doi":"10.62347/IOFY5604","DOIUrl":"10.62347/IOFY5604","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the pro-apoptotic effects of Indirubin, a traditional Chinese medicine, on ovarian cancer SKOV3 cell line and to explore its underlying mechanisms.</p><p><strong>Methods: </strong>Ovarian cancer SKOV3 cells were divided into a control group (cells cultured normally) and an experimental group (cells cultured in medium containing Indirubin). SKOV3 cells at the logarithmic phase were treated with Indirubin at various concentrations. Cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8) assay and 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay, while apoptosis was detected by flow cytometry, TdT-mediated dUTP Nick-End Labeling (TUNEL) staining, and immunofluorescence. Transcriptome sequencing was conducted to screen for apoptosis-related factors. qPCR and western blot were used to detect the mRNA and protein expression on added of molecules related to mitochondrial permeability transition pores.</p><p><strong>Results: </strong>MTT assay showed that Indirubin inhibited the growth of SKOV3 cells in both plate and sphere cultures, with IC<sub>50</sub> values of 3.003 μM (plate culture) and 4.253 μM (sphere culture), respectively. Indirubin showed a lower inhibitory concentration than cisplatin (IC<sub>50</sub> 3.687 μM in plate culture and 7.023 μM in sphere culture), and its effect was comparable to adriamycin. Flow cytometry revealed an increase in apoptosis rates in SKOV3 cells treated with Indirubin. Transcriptome sequencing indicated significant changes in the transcription of various apoptosis-related genes, particularly those involved in the mitochondrial apoptosis pathway, such as Bcl-2-associated X protein (Bax) and Bcl2 associated agonist of cell death (Bad). After Indirubin treatment, the mRNA and protein expression levels of mitochondrial channel-related genes Cyclophilin D (CyPD), adenine nucleotide translocator 1 (ANT1), and voltage-dependent anion channel (VADC) were significantly elevated (all P < 0.05). By regulating the mitochondrial membrane permeability through the Bcl-2 family members, Indirubin promoted apoptosis in SKOV3 cells.</p><p><strong>Conclusion: </strong>Indirubin inhibits the proliferation and promotes the apoptosis of ovarian cancer cells, exerting an anti-tumor effect. Its pro-apoptotic action is closely related to the mitochondrial apoptosis pathway.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"6119-6129"},"PeriodicalIF":1.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodal ultrasound plus tumor markers demonstrates a high value in enhanced diagnosis of breast cancer. 多模态超声加肿瘤标记物在增强乳腺癌诊断方面具有很高的价值。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.62347/QVCI6027
Na Li, Ming Li, Fengsheng Zhou

Objective: To determine the diagnostic value of multimodal ultrasound combined with tumor markers in breast cancer (BC).

Methods: A retrospective analysis was conducted on 198 patients with breast lesions treated at the Affiliated Wuxi People's Hospital of Nanjing Medical University between May 2020 and May 2023. All patients underwent multimodal ultrasound and tumor marker testing. Among the 198 patients, 88 patients were pathologically diagnosed with benign disease (benign group) and 110 patients were pathologically diagnosed with malignant disease (malignant group). With the pathological results as the gold standard, the benign and malignant results from different diagnostic methods were compared, focusing on specificity, sensitivity and accuracy.

Results: The areas under the curves (AUCs) of carbohydrate antigen 153 (CA153), CA125, and carcinoembryonic antigen (CEA) for diagnosing BC were 0.810, 0.812, and 0.790, respectively. When these tumor markers were used in combination for diagnosing BC, the AUC increased to 0.928. The AUC of multimodal ultrasound alone in diagnosing BC was 0.845. Additionally, the AUC of multimodal ultrasound combined with tumor markers in diagnosing BC reached 0.971, with the corresponding specificity, sensitivity and accuracy of 90.00%, 94.43% and 91.92%, respectively.

Conclusion: In patients with early BC, the combination of multimodal ultrasound and tumor marker detection significantly improves the accuracy of diagnosing benign and malignant breast lesions compared to using either modality alone.

目的:确定多模态超声联合肿瘤标记物对乳腺癌(BC)的诊断价值:方法:对2020年5月至2023年5月期间在南京医科大学附属无锡人民医院接受治疗的198例乳腺病变患者进行回顾性分析:对2020年5月至2023年5月期间在南京医科大学附属无锡人民医院接受治疗的198例乳腺病变患者进行回顾性分析。所有患者均接受了多模态超声和肿瘤标志物检测。在198例患者中,88例经病理诊断为良性疾病(良性组),110例经病理诊断为恶性疾病(恶性组)。以病理结果为金标准,对不同诊断方法得出的良性和恶性结果进行比较,重点关注特异性、敏感性和准确性:碳水化合物抗原 153(CA153)、CA125 和癌胚抗原(CEA)诊断 BC 的曲线下面积(AUC)分别为 0.810、0.812 和 0.790。当这些肿瘤标记物联合用于诊断 BC 时,AUC 增加到 0.928。单独使用多模态超声诊断 BC 的 AUC 为 0.845。此外,多模态超声联合肿瘤标志物诊断 BC 的 AUC 达到 0.971,相应的特异性、敏感性和准确性分别为 90.00%、94.43% 和 91.92%:结论:对于早期乳腺良恶性肿瘤患者,联合使用多模态超声和肿瘤标记物检测与单独使用其中一种方法相比,能显著提高诊断乳腺良恶性病变的准确性。
{"title":"Multimodal ultrasound plus tumor markers demonstrates a high value in enhanced diagnosis of breast cancer.","authors":"Na Li, Ming Li, Fengsheng Zhou","doi":"10.62347/QVCI6027","DOIUrl":"10.62347/QVCI6027","url":null,"abstract":"<p><strong>Objective: </strong>To determine the diagnostic value of multimodal ultrasound combined with tumor markers in breast cancer (BC).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 198 patients with breast lesions treated at the Affiliated Wuxi People's Hospital of Nanjing Medical University between May 2020 and May 2023. All patients underwent multimodal ultrasound and tumor marker testing. Among the 198 patients, 88 patients were pathologically diagnosed with benign disease (benign group) and 110 patients were pathologically diagnosed with malignant disease (malignant group). With the pathological results as the gold standard, the benign and malignant results from different diagnostic methods were compared, focusing on specificity, sensitivity and accuracy.</p><p><strong>Results: </strong>The areas under the curves (AUCs) of carbohydrate antigen 153 (CA153), CA125, and carcinoembryonic antigen (CEA) for diagnosing BC were 0.810, 0.812, and 0.790, respectively. When these tumor markers were used in combination for diagnosing BC, the AUC increased to 0.928. The AUC of multimodal ultrasound alone in diagnosing BC was 0.845. Additionally, the AUC of multimodal ultrasound combined with tumor markers in diagnosing BC reached 0.971, with the corresponding specificity, sensitivity and accuracy of 90.00%, 94.43% and 91.92%, respectively.</p><p><strong>Conclusion: </strong>In patients with early BC, the combination of multimodal ultrasound and tumor marker detection significantly improves the accuracy of diagnosing benign and malignant breast lesions compared to using either modality alone.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"5497-5506"},"PeriodicalIF":1.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive analysis of Aspirin and Apixaban: thedevelopment, validation, and forced degradation studies of bulk drugs and in-house capsule formulations using the RP-HPLC method. 阿司匹林和阿哌沙班的综合分析:使用 RP-HPLC 方法对散装药物和内部胶囊制剂进行开发、验证和强制降解研究。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.62347/VYDX5901
Tarang Patel, Mehul Patel, Umang Shah, Ashish Patel, Swayamprakash Patel, Nilay Solanki, Siddharth Shah

Objectives: This study aimed to develop a robust Reverse Phase-High-Performance Liquid Chromatography (RP-HPLC) method for simultaneous determination of Aspirin (ASP) and Apixaban (API) in bulk and in-house capsule formulations.

Methods: The separation was conducted on a Phenomenex Luna C18 column using a Shimadzu LC20AT High-performance liquid chromatography (HPLC) system. The mobile phase consisted of 40:60 Acetonitrile (ACN): phosphate buffer (pH 4) modified by O-Phosphoric Acid (OPA). The parameters included a flow rate of 1 ml/min, a column temperature of 30°C, and Ultra-Violet (UV) detection at 227 nm. Method validation encompassed linearity, precision (Intraday and Interday), accuracy (% Recovery), and sensitivity (Limit of Detection (LOD) and Limit of Quantification (LOQ)). Stability testing followed The International Council for Harmonization (ICH) guidelines.

Results: The developed method demonstrated reliable separation of Aspirin and Apixaban with retention times of 5.37 min and 7.10 min, respectively. It exhibited linearity over the concentration ranges of 50-300 μg/mL for Aspirin and 5-15 μg/mL for Apixaban. The recovery percentage ranged from 90.02% to 101% for Aspirin and 98.18% to 101.18% for Apixaban. LOD and LOQ were determined as 0.84 μg/mL and 2.55 μg/mL for Aspirin, and 0.41 μg/mL and 1.24 μg/mL for Apixaban, respectively. Stability testing confirmed the method's robustness under various stress conditions.

Conclusions: The validated RP-HPLC method offers a reliable tool for routine analysis of Aspirin and Apixaban in pharmaceutical formulations, highlighting its potential for combined dosage applications and routine quality control.

研究目的本研究旨在开发一种稳健的反相高效液相色谱(RP-HPLC)方法,用于同时测定散装和内部胶囊制剂中的阿司匹林(ASP)和阿哌沙班(API):采用岛津 LC20AT 高效液相色谱(HPLC)系统,在 Phenomenex Luna C18 色谱柱上进行分离。流动相为 40:60 乙腈(ACN):经 O-磷酸(OPA)改良的磷酸盐缓冲液(pH 4)。参数包括流速 1 ml/min、柱温 30°C、紫外检测波长 227 nm。方法验证包括线性、精确度(日内和日间)、准确度(回收率%)和灵敏度(检测限(LOD)和定量限(LOQ))。稳定性测试遵循了国际协调理事会(ICH)的指导原则:所开发的方法可靠地分离了阿司匹林和阿哌沙班,保留时间分别为 5.37 分钟和 7.10 分钟。阿司匹林和阿哌沙班在 50-300 μg/mL 和 5-15 μg/mL 的浓度范围内呈线性关系。阿司匹林的回收率为 90.02% 至 101%,阿哌沙班的回收率为 98.18% 至 101.18%。阿司匹林的最低检出限(LOD)和最低定量限(LOQ)分别为0.84 μg/mL和2.55 μg/mL,阿哌沙班的最低检出限(LOD)和最低定量限(LOQ)分别为0.41 μg/mL和1.24 μg/mL。稳定性测试证实了该方法在各种压力条件下的稳健性:经过验证的 RP-HPLC 方法为药物制剂中阿司匹林和阿哌沙班的常规分析提供了可靠的工具,凸显了其在复合制剂应用和常规质量控制方面的潜力。
{"title":"Comprehensive analysis of Aspirin and Apixaban: thedevelopment, validation, and forced degradation studies of bulk drugs and <i>in-house</i> capsule formulations using the RP-HPLC method.","authors":"Tarang Patel, Mehul Patel, Umang Shah, Ashish Patel, Swayamprakash Patel, Nilay Solanki, Siddharth Shah","doi":"10.62347/VYDX5901","DOIUrl":"10.62347/VYDX5901","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to develop a robust Reverse Phase-High-Performance Liquid Chromatography (RP-HPLC) method for simultaneous determination of Aspirin (ASP) and Apixaban (API) in bulk and in-house capsule formulations.</p><p><strong>Methods: </strong>The separation was conducted on a Phenomenex Luna C<sub>18</sub> column using a Shimadzu LC20AT High-performance liquid chromatography (HPLC) system. The mobile phase consisted of 40:60 Acetonitrile (ACN): phosphate buffer (pH 4) modified by O-Phosphoric Acid (OPA). The parameters included a flow rate of 1 ml/min, a column temperature of 30°C, and Ultra-Violet (UV) detection at 227 nm. Method validation encompassed linearity, precision (Intraday and Interday), accuracy (% Recovery), and sensitivity (Limit of Detection (LOD) and Limit of Quantification (LOQ)). Stability testing followed The International Council for Harmonization (ICH) guidelines.</p><p><strong>Results: </strong>The developed method demonstrated reliable separation of Aspirin and Apixaban with retention times of 5.37 min and 7.10 min, respectively. It exhibited linearity over the concentration ranges of 50-300 μg/mL for Aspirin and 5-15 μg/mL for Apixaban. The recovery percentage ranged from 90.02% to 101% for Aspirin and 98.18% to 101.18% for Apixaban. LOD and LOQ were determined as 0.84 μg/mL and 2.55 μg/mL for Aspirin, and 0.41 μg/mL and 1.24 μg/mL for Apixaban, respectively. Stability testing confirmed the method's robustness under various stress conditions.</p><p><strong>Conclusions: </strong>The validated RP-HPLC method offers a reliable tool for routine analysis of Aspirin and Apixaban in pharmaceutical formulations, highlighting its potential for combined dosage applications and routine quality control.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"5311-5325"},"PeriodicalIF":1.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of influencing factors of dry eyes after cataract surgery and construction of a prediction model. 分析白内障手术后干眼症的影响因素并构建预测模型。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.62347/WXHN4015
Caifeng Shi, Lijun Chen

Objective: To identify the influencing factors of dry eyes after cataract surgery and construct a prediction model to provide a reference for ophthalmologists in assessing the risk of postoperative dry eyes.

Methods: A retrospective study was conducted from January 2023 to April 2024, involving 219 patients (219 eyes) who underwent phacoemulsification with intraocular lens implantation at the Department of Ophthalmology, Ninth People's Hospital of Suzhou. Patients were divided into two groups based on the presence or absence of dry eyes at 2 weeks postoperatively. Data from both groups were analyzed to determine the influencing factors of dry eyes after cataract surgery. A nomogram prediction model was constructed using R software. The model's discrimination was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC), and model calibration was assessed using the Hosmer-Lemeshow (H-L) goodness-of-fit test and the Bootstrap method (self-sampling technique). Decision curve analysis was employed to evaluate the clinical utility of the model.

Results: Among the 219 cataract patients, 53 (24.20%) developed dry eyes during the 2-week follow-up period. Multivariate logistic regression analysis identified smoking (OR = 1.809, P = 0.037), diabetes mellitus (OR = 3.248, P = 0.002), elevated IL-6 (OR = 3.019, P = 0.016), a high Hospital Anxiety and Depression Scale (HADS) score (OR = 2.147, P = 0.029), and longer surgical incision length (OR = 2.995, P = 0.014) as significant risk factors for postoperative dry eye. The AUC of the nomogram model was 0.857 (95% CI: 0.803-0.913), and the H-L goodness-of-fit test showed no statistical significance (χ2 = 4.472, P = 0.812), indicating good discrimination and calibration of the model. The average absolute error between predicted and actual probabilities after 1000 Bootstrap iterations was 0.021. Decision curve analysis demonstrated that the net benefit of the model was higher than the two extreme scenarios.

Conclusion: Postoperative dry eyes in cataract patients is associated with smoking, diabetes, elevated IL-6, high HADS scores, and longer incision lengths. The nomogram model demonstrates good predictive capability for assessing the risk of dry eyes after cataract surgery.

目的找出白内障术后干眼症的影响因素,构建预测模型,为眼科医生评估术后干眼症风险提供参考:回顾性研究:2023年1月至2024年4月,在苏州市第九人民医院眼科接受白内障超声乳化联合人工晶体植入术的患者219例(219眼)。根据术后 2 周是否出现干眼症将患者分为两组。对两组患者的数据进行分析,以确定白内障手术后干眼症的影响因素。使用 R 软件构建了一个提名图预测模型。使用接收者操作特征曲线(ROC)下面积(AUC)评估了模型的区分度,并使用Hosmer-Lemeshow(H-L)拟合优度检验和Bootstrap方法(自采样技术)评估了模型的校准。采用决策曲线分析评估模型的临床实用性:在 219 名白内障患者中,有 53 人(24.20%)在两周的随访期间出现干眼症。多变量逻辑回归分析发现,吸烟(OR = 1.809,P = 0.037)、糖尿病(OR = 3.248,P = 0.002)、IL-6 升高(OR = 3.019,P = 0.016)、医院焦虑和抑郁量表(HADS)评分高(OR = 2.147,P = 0.029)和手术切口长度长(OR = 2.995,P = 0.014)是术后干眼症的重要风险因素。提名图模型的 AUC 为 0.857 (95% CI: 0.803-0.913),H-L 拟合度检验显示无统计学意义 (χ2 = 4.472, P = 0.812),表明模型具有良好的区分度和校准性。经过 1000 次 Bootstrap 迭代后,预测概率与实际概率之间的平均绝对误差为 0.021。决策曲线分析表明,该模型的净收益高于两种极端情况:结论:白内障患者术后干眼症与吸烟、糖尿病、IL-6 升高、HADS 评分高和切口长度长有关。提名图模型在评估白内障术后干眼症风险方面具有良好的预测能力。
{"title":"Analysis of influencing factors of dry eyes after cataract surgery and construction of a prediction model.","authors":"Caifeng Shi, Lijun Chen","doi":"10.62347/WXHN4015","DOIUrl":"10.62347/WXHN4015","url":null,"abstract":"<p><strong>Objective: </strong>To identify the influencing factors of dry eyes after cataract surgery and construct a prediction model to provide a reference for ophthalmologists in assessing the risk of postoperative dry eyes.</p><p><strong>Methods: </strong>A retrospective study was conducted from January 2023 to April 2024, involving 219 patients (219 eyes) who underwent phacoemulsification with intraocular lens implantation at the Department of Ophthalmology, Ninth People's Hospital of Suzhou. Patients were divided into two groups based on the presence or absence of dry eyes at 2 weeks postoperatively. Data from both groups were analyzed to determine the influencing factors of dry eyes after cataract surgery. A nomogram prediction model was constructed using R software. The model's discrimination was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC), and model calibration was assessed using the Hosmer-Lemeshow (H-L) goodness-of-fit test and the Bootstrap method (self-sampling technique). Decision curve analysis was employed to evaluate the clinical utility of the model.</p><p><strong>Results: </strong>Among the 219 cataract patients, 53 (24.20%) developed dry eyes during the 2-week follow-up period. Multivariate logistic regression analysis identified smoking (OR = 1.809, P = 0.037), diabetes mellitus (OR = 3.248, P = 0.002), elevated IL-6 (OR = 3.019, P = 0.016), a high Hospital Anxiety and Depression Scale (HADS) score (OR = 2.147, P = 0.029), and longer surgical incision length (OR = 2.995, P = 0.014) as significant risk factors for postoperative dry eye. The AUC of the nomogram model was 0.857 (95% CI: 0.803-0.913), and the H-L goodness-of-fit test showed no statistical significance (χ<sup>2</sup> = 4.472, P = 0.812), indicating good discrimination and calibration of the model. The average absolute error between predicted and actual probabilities after 1000 Bootstrap iterations was 0.021. Decision curve analysis demonstrated that the net benefit of the model was higher than the two extreme scenarios.</p><p><strong>Conclusion: </strong>Postoperative dry eyes in cataract patients is associated with smoking, diabetes, elevated IL-6, high HADS scores, and longer incision lengths. The nomogram model demonstrates good predictive capability for assessing the risk of dry eyes after cataract surgery.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"5418-5426"},"PeriodicalIF":1.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical efficacy of recombinant human interferon α-2b gel combined with LEEP conization in treating cervical intraepithelial neoplasia with comorbid high-risk HPV infection. 重组人干扰素α-2b凝胶联合LEEP锥切术治疗合并高危人乳头瘤病毒感染的宫颈上皮内瘤变的临床疗效。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.62347/ABUY6253
Shaohua Zhang, Xialing Huang, Xiaoxia Liu

Objective: To evaluate the clinical efficacy of recombinant human interferon α-2b (rHuINF α-2b) gel combined with loop electrosurgical excision procedure (LEEP) conization in treating cervical intraepithelial neoplasia (CIN) with comorbid high-risk human papillomavirus (HR-HPV) infection.

Methods: A retrospective analysis was conducted on the clinical data of 202 CIN patients with HR-HPV infection who were treated at Wuhan Yaxin General Hospital between July 2021 and February 2024. Among these patients, 106 received treatment with rHuINF α-2b gel combined with LEEP conization (study group), and the other 96 were treated with LEEP conization alone (control group). The two groups were compared in terms of efficacy on CIN, HPV clearance, vaginal bleeding duration, hospital stay and occurrence of adverse reactions. Patient prognosis within six months post-treatment was analyzed, and the risk factors affecting prognosis were analyzed through logistic regression.

Results: The control group experienced notably longer vaginal bleeding duration and hospital stay than the study group (all P<0.0001). The study group showed a notably higher cure rate of CIN than the control group and presented a notably lower rate of persistent or residual CIN than the control group (P=0.0026). Six months after treatment, the total effective HPV clearance rate in the study group was greatly higher than that in the control group (P=0.0010). However, there was no insignificant difference between the two groups in the incidence of adverse reactions (P=0.4807). According to logistic regression analysis, age, grade of CIN, course of disease and treatment regimen were independent risk factors for patient prognosis.

Conclusion: For CIN patients with comorbid high HPV risk infection, rHuINF α-2b gel combined with LEEP conization can effectively treat CIN, clear HPV, and shorten the duration of vaginal bleeding and hospitalization, without increasing adverse reactions. In addition, age, grade of CIN, course of disease and treatment regimen were independent risk factors for the prognosis of patients.

目的评估重组人干扰素α-2b(rHuINF α-2b)凝胶联合环形电切术(LEEP)治疗合并高危人乳头瘤病毒(HR-HPV)感染的宫颈上皮内瘤变(CIN)的临床疗效:方法:对2021年7月至2024年2月期间在武汉雅馨综合医院接受治疗的202例合并HR-HPV感染的CIN患者的临床资料进行回顾性分析。在这些患者中,106人接受了rHuINF α-2b凝胶联合LEEP锥切术治疗(研究组),另外96人仅接受了LEEP锥切术治疗(对照组)。两组在对 CIN 的疗效、HPV 清除率、阴道出血时间、住院时间和不良反应发生率方面进行了比较。分析了患者治疗后六个月内的预后,并通过逻辑回归分析了影响预后的风险因素:结果:对照组的阴道出血时间和住院时间明显长于研究组(均为 PC):对于合并HPV高危感染的CIN患者,rHuINF α-2b凝胶联合LEEP锥切术可有效治疗CIN,清除HPV,缩短阴道出血时间和住院时间,且不会增加不良反应。此外,年龄、CIN 级别、病程和治疗方案是影响患者预后的独立危险因素。
{"title":"Clinical efficacy of recombinant human interferon α-2b gel combined with LEEP conization in treating cervical intraepithelial neoplasia with comorbid high-risk HPV infection.","authors":"Shaohua Zhang, Xialing Huang, Xiaoxia Liu","doi":"10.62347/ABUY6253","DOIUrl":"10.62347/ABUY6253","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical efficacy of recombinant human interferon α-2b (rHuINF α-2b) gel combined with loop electrosurgical excision procedure (LEEP) conization in treating cervical intraepithelial neoplasia (CIN) with comorbid high-risk human papillomavirus (HR-HPV) infection.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of 202 CIN patients with HR-HPV infection who were treated at Wuhan Yaxin General Hospital between July 2021 and February 2024. Among these patients, 106 received treatment with rHuINF α-2b gel combined with LEEP conization (study group), and the other 96 were treated with LEEP conization alone (control group). The two groups were compared in terms of efficacy on CIN, HPV clearance, vaginal bleeding duration, hospital stay and occurrence of adverse reactions. Patient prognosis within six months post-treatment was analyzed, and the risk factors affecting prognosis were analyzed through logistic regression.</p><p><strong>Results: </strong>The control group experienced notably longer vaginal bleeding duration and hospital stay than the study group (all P<0.0001). The study group showed a notably higher cure rate of CIN than the control group and presented a notably lower rate of persistent or residual CIN than the control group (P=0.0026). Six months after treatment, the total effective HPV clearance rate in the study group was greatly higher than that in the control group (P=0.0010). However, there was no insignificant difference between the two groups in the incidence of adverse reactions (P=0.4807). According to logistic regression analysis, age, grade of CIN, course of disease and treatment regimen were independent risk factors for patient prognosis.</p><p><strong>Conclusion: </strong>For CIN patients with comorbid high HPV risk infection, rHuINF α-2b gel combined with LEEP conization can effectively treat CIN, clear HPV, and shorten the duration of vaginal bleeding and hospitalization, without increasing adverse reactions. In addition, age, grade of CIN, course of disease and treatment regimen were independent risk factors for the prognosis of patients.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"5649-5658"},"PeriodicalIF":1.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the oncogenic significance of thymidylate synthase in human cancers. 揭示胸苷酸合成酶在人类癌症中的致癌意义。
IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.62347/IRUZ1011
Yibo Geng, Luyang Xie, Yang Wang, Yan Wang

Objective: Thymidylate synthase (TYMS) constitutes a pivotal and potent target in the context of chemoresistance. However, the oncogenic role of TYMS has received insufficient attention.

Methods: Leveraging data from the Cancer Genome Atlas (TCGA) and various public databases, we conducted an extensive investigation into the oncogenic role of TYMS across 33 cancer types. Subsequently, TYMS was inhibited using small interfering RNA (siRNA) in four different cell lines, and cell proliferation and migration were assessed using CellTiter-Glo and Transwell assays.

Results: TYMS exhibited pronounced expression across a spectrum of cancers and demonstrated associations with clinical outcome in diverse cancer patient cohorts. Furthermore, genetic alterations were identified as potential influencers of overall survival in specific tumor types. Notably, the expression of thymidylate synthase correlated with tumor-infiltrating CD4+ cells in select cancers. Additionally, the functional mechanism of TYMS encompassed nucleotidase activity, chromosome segregation, and DNA replication progress. In vitro experiments further substantiated these findings, demonstrating that the suppression of TYMS impeded the cell growth and invasive capabilities of HeLa, A549, 786-O, and U87_MG cells.

Conclusions: This study furnishes a comprehensive understanding of the oncogenic role played by TYMS in human tumors.

目的:胸苷酸合成酶(TYMS)是化疗耐药性的一个关键和有效靶点。然而,TYMS的致癌作用尚未得到足够的重视:利用癌症基因组图谱(TCGA)和各种公共数据库的数据,我们对 33 种癌症类型中 TYMS 的致癌作用进行了广泛调查。随后,我们在四种不同的细胞系中使用小干扰 RNA(siRNA)抑制了 TYMS,并使用 CellTiter-Glo 和 Transwell 检测法评估了细胞的增殖和迁移:结果:TYMS在多种癌症中均有明显表达,并在不同癌症患者群中显示出与临床结果的相关性。此外,在特定肿瘤类型中,基因改变被认为是影响总体生存的潜在因素。值得注意的是,在某些癌症中,胸苷酸合成酶的表达与肿瘤浸润的 CD4+ 细胞相关。此外,TYMS的功能机制还包括核苷酸酶活性、染色体分离和DNA复制进展。体外实验进一步证实了这些发现,表明抑制 TYMS 会阻碍 HeLa、A549、786-O 和 U87_MG 细胞的生长和侵袭能力:本研究全面揭示了 TYMS 在人类肿瘤中的致癌作用。
{"title":"Unveiling the oncogenic significance of thymidylate synthase in human cancers.","authors":"Yibo Geng, Luyang Xie, Yang Wang, Yan Wang","doi":"10.62347/IRUZ1011","DOIUrl":"10.62347/IRUZ1011","url":null,"abstract":"<p><strong>Objective: </strong>Thymidylate synthase (TYMS) constitutes a pivotal and potent target in the context of chemoresistance. However, the oncogenic role of TYMS has received insufficient attention.</p><p><strong>Methods: </strong>Leveraging data from the Cancer Genome Atlas (TCGA) and various public databases, we conducted an extensive investigation into the oncogenic role of TYMS across 33 cancer types. Subsequently, TYMS was inhibited using small interfering RNA (siRNA) in four different cell lines, and cell proliferation and migration were assessed using CellTiter-Glo and Transwell assays.</p><p><strong>Results: </strong>TYMS exhibited pronounced expression across a spectrum of cancers and demonstrated associations with clinical outcome in diverse cancer patient cohorts. Furthermore, genetic alterations were identified as potential influencers of overall survival in specific tumor types. Notably, the expression of thymidylate synthase correlated with tumor-infiltrating CD4+ cells in select cancers. Additionally, the functional mechanism of TYMS encompassed nucleotidase activity, chromosome segregation, and DNA replication progress. <i>In vitro</i> experiments further substantiated these findings, demonstrating that the suppression of TYMS impeded the cell growth and invasive capabilities of HeLa, A549, 786-O, and U87_MG cells.</p><p><strong>Conclusions: </strong>This study furnishes a comprehensive understanding of the oncogenic role played by TYMS in human tumors.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"16 10","pages":"5228-5247"},"PeriodicalIF":1.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of translational research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1